OSP News

Long-Acting Insulin Levemir will be Discontinued in 2024

Posted: 11/27/2023

Novo Nordisk® has announced that it will discontinue its long-acting insulin Levemir in the United States. Key factors in the decision include global manufacturing constraints, reduced patient access and available alternatives.

Supply disruptions are planned to start in mid-January, followed by discontinuation of the Levemir injection pen in April and of Levemir vials by the end of 2024.

Click here for more information.

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.

x

OSP Technical Support